FATE THERAPEUTICS INC (FATE)
Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis
Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis
Creative Media & Community Trust Corporation Reports 2026 Second Quarter Results
Aurora Mobile and Exabytes Sign Three-Year Strategic MoU to Bring AI-Powered Customer Engagement to Businesses Across Southeast Asia
Beyond Meat Announces Effectiveness of 1-for-30 Reverse Stock Split
OLD REPUBLIC DECLARES THIRD QUARTER REGULAR DIVIDEND OF 31.5 CENTS PER SHARE
Core Scientific Completes Acquisition of Polaris DS, Advancing Planned Muskogee Expansion to 1.5 GW of Gross Power
J & J SNACK FOODS CORP. ANNOUNCES QUARTERLY CASH DIVIDEND
JOYY to Announce Second Quarter 2026 Financial Results on August 25, 2026
Engine Capital Urges H.B. Fuller’s Board of Directors to Run a Market Check for the Building Adhesive Solutions Segment and the Entire Company
Bank Leumi Partners with Galaxy to be the First Bank in Israel to Offer Digital Asset Trading